The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations
PHASE1CompletedINTERVENTIONAL
Enrollment
15
Participants
Timeline
Start Date
March 18, 2019
Primary Completion Date
March 31, 2019
Study Completion Date
March 31, 2019
Conditions
Opioid Intoxication
Interventions
DRUG
Naltrexone Hydrochloride
50 mg per os naltrexone hydrochloride
Trial Locations (1)
K1A 0K2
Department of National Defence, Ottawa
All Listed Sponsors
lead
Timothy Smith
OTHER_GOV
NCT03879460 - The Evaluation of Safety and Tolerance of Commercially Available Naltrexone Administered Daily - Assessment for CBRN Operations | Biotech Hunter | Biotech Hunter